Research Summary

Analyzed using Evidence Intelligence™

Omnipod DASH Improves Treatment Satisfaction in Type 1 Diabetes

Last updated August 29, 2026

Key finding

ΔDTQ-current score of 16.4 [21.2] vs 0.0 [12.8]; P < .001

This study compared treatment satisfaction between the Omnipod DASH Insulin Management System and Usual Care in adults with Type 1 Diabetes, finding significant improvements with the Omnipod.

Quick read

Study at a glance

The essential study design details in one scan.

EvidenceScore™

Moderate

Study type

RCTs

Follow-up

Medium-Term (3–12 mo)

Risk of bias

Some Concerns

Save research, organize studies, and quickly find important evidence again.

Plain-language summary

What this paper says

A plain-language read of the study’s main message and where it applies.

Study focus

This study compared treatment satisfaction between the Omnipod DASH Insulin Management System and Usual Care in adults with Type 1 Diabetes, finding significant improvements with the Omnipod.

Clinical relevance

Improving treatment satisfaction and glycemic control is crucial for individuals with Type 1 Diabetes, as it can lead to better adherence to treatment and overall health outcomes. The Omnipod DASH system may offer a more effective and user-friendly alternative to traditional insulin delivery methods.

Keep in mind

The study may have limited generalizability due to its specific population. Potential biases in self-reported measures of satisfaction. Short duration of follow-up may not capture long-term effects.

Published in

Journal Reference

Publication details and source links for this paper.

Yee WK, Cheng YY, Katerina K, et al. Treatment Satisfaction with the Omnipod DASH Insulin Management System Compared to Usual Care in Adults with Type 1 Diabetes. The Journal of Clinical Endocrinology and Metabolism. 2024;109(8):1984-1995. doi:10.1210/clinem/dgae088

View DOI View on PubMed View on PMC

Main Effects

The Omnipod group showed a significant increase in Diabetes Technology Questionnaire current score by 16.4 (P < .001).

HbA1c levels decreased by -0.4% in the Omnipod group compared to -0.1% in the Usual Care group (P = 0.037).

Time in range improved significantly at the end extension for the Omnipod group (5.6% change; P = .016).

Evidence network

How this study fits

Understand where this research contributes within the broader evidence network.

Evidence Context

This study contributes evidence to Insulin therapy, Omnipod DASH Insulin Management System and HbA1c, Type 1 diabetes knowledge score, Time in range.

This study contributes evidence to

Intervention

Insulin therapy

Outcome

HbA1c

Evidence topic

HbA1c Reduction

Primary intervention

Insulin therapy

Primary outcomes

HbA1c
Type 1 diabetes knowledge score
Time in range

Evidence topics

HbA1c Reduction Glycemic Control Insulin Therapies

Primary intervention

Insulin therapy

Primary outcomes

HbA1c Type 1 diabetes knowledge score Time in range

Evidence relationships

Intervention and outcome relationships this study adds to the evidence network.

Evidence pairs

Relationships

Evidence topics

contributes_evidence

Editorial context

Why this study matters

See why this paper is useful beyond its individual results.

Evidence network role

This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.

Moderate contributionModerate confidenceNetwork score: 68

Why it is useful

Contributes to 5 evidence relationships
Includes primary outcome data
Linked to 3 direct semantic evidence topics

Topic contributions

Evidence topic

Contributes evidence

Evidence topic

Contributes evidence

Evidence topic

Contributes evidence

Add related evidence to your Evidence Tracker

Save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.

Primary evidence

Evidence relationship

Insulin Therapies and HbA1c

Related evidence

Evidence topic

HbA1c Reduction

Save evidence

Evidence topic

Glycemic Control

Save evidence

Core evidence

Study findings

The primary outcomes reported in this study.

HbA1c

Insulin therapy → HbA1c

Evidence Intelligence™

EvidenceScore™: 83; Strong
ImpactScore™: 83; Positive
ConsistencyScore™: 67; generally_consistent

Based on 6 studies

Add to Evidence Tracker

Type 1 diabetes knowledge score

Insulin therapy → Type 1 diabetes knowledge score

Evidence Intelligence™

EvidenceScore™: Emerging; Score 59 · Based on 1 study
ImpactScore™: 50; Neutral
ConsistencyScore™: unclear; Not enough independent studies

Based on 1 study

Add to Evidence Tracker

HbA1c

Omnipod DASH Insulin Management System → HbA1c

Evidence Intelligence™

EvidenceScore™: Emerging; Score 59 · Based on 1 study
ImpactScore™: 100; Very Positive
ConsistencyScore™: unclear; Not enough independent studies

Based on 1 study

Add to Evidence Tracker

Time in range

Omnipod DASH Insulin Management System → Time in range

Evidence Intelligence™

EvidenceScore™: Emerging; Score 59 · Based on 1 study
ImpactScore™: 50; Neutral
ConsistencyScore™: unclear; Not enough independent studies

Based on 1 study

Add to Evidence Tracker

Type 1 diabetes knowledge score

Omnipod DASH Insulin Management System → Type 1 diabetes knowledge score

Evidence Intelligence™

EvidenceScore™: Emerging; Score 59 · Based on 1 study
ImpactScore™: 100; Very Positive
ConsistencyScore™: unclear; Not enough independent studies

Based on 1 study

Add to Evidence Tracker

Evidence Library

Build your evidence library

Save research, organize studies, and quickly find important evidence again.

Evidence Suggest

Omnipod users reported 16.4 points higher satisfaction (P < .001).
HbA1c decreased by -0.4% in the Omnipod group (P = 0.037).
Time in range improved by 5.6% at extension (P = .016).

Who this applies to

Adults diagnosed with Type 1 Diabetes.
Individuals currently using insulin therapy.

Keep in Mind

Results may not apply to younger populations or those with Type 2 Diabetes.
Further studies are needed to assess long-term outcomes.
Variability in individual responses to treatment may exist.

Between the Lines

The study may have limited generalizability due to its specific population.
Potential biases in self-reported measures of satisfaction.
Short duration of follow-up may not capture long-term effects.

Evidence Library

Build your evidence library

Save research, organize studies, and quickly find important evidence again.

Connected Evidence

Explore related studies, evidence collections, and research questions.

Relationships organized using the Dediabetes Evidence Intelligence™ framework.

This study contributes to evidence on Insulin Therapies and HbA1c, Insulin Therapies and CGM Time in Range.

Related evidence relationships

Explore in Evidence Explorer

This study contributes to the evidence on the following intervention-outcome relationships.

Medications

Detailed evidence

Insulin Therapies → HbA1c

Medications

Evidence Intelligence™

EvidenceScore™: 83; Strong
ImpactScore™: 83; Positive
ConsistencyScore™: 67; generally_consistent

Based on 6 studies

View evidence

Medications

Detailed evidence

Insulin Therapies → CGM Time in Range

Medications

Evidence Intelligence™

EvidenceScore™: 82; Strong
ImpactScore™: 70; Positive
ConsistencyScore™: 60; generally_consistent

Based on 5 studies

View evidence

Included in these evidence collections

Curated evidence collections and hubs this study is part of.

HbA1c Evidence Hub

All studies measuring HbA1c

6 studies

outcome_hub

Measures HbA1c as a key outcome.

Insulin Therapies Evidence Hub

All studies on Insulin Therapies

6 studies

intervention_hub

Contributes to Insulin Therapies evidence base.

CGM Time in Range Evidence Hub

All studies measuring CGM Time in Range

5 studies

outcome_hub

Measures CGM Time in Range as a key outcome.

Recent Diabetes Research

Latest published studies

recency_collection

Published within the last 2 years.

Explore more in Evidence Explorer

Jump to pre-filtered views in Evidence Explorer.

All studies on Insulin therapy and HbA1c

Intervention: Insulin therapyOutcome: HbA1c

6 results

All studies on Insulin therapy and Time in range

Intervention: Insulin therapyOutcome: Time in range

5 results

All studies on Insulin therapy

Intervention: Insulin therapy

6 results

All studies measuring HbA1c

Outcome: HbA1c

6 results

All studies measuring Time in range

Outcome: Time in range

5 results

Questions answered by this study

Generated from the study's connected evidence using Evidence Intelligence™.

Does Insulin Therapies improve HbA1c?

Strong Evidence

Insulin Therapies may improve HbA1c.

ConsistencyScore™: Results are generally consistent across studies.

Ranked evidence signals

1
HbA1c
EvidenceScore™ Strong | EvidenceScore™ 83.3 | moderate positive | ConsistencyScore™ Generally Consistent | 1 study

Why this answer: This answer is based on 15 supporting studies with generally consistent results and a positive effect signal.

Limitations

Population details are unavailable.

View Full Evidence

Does Omnipod DASH Insulin Management System improve HbA1c?

Emerging Evidence

Omnipod DASH Insulin Management System appears to improve HbA1c.

ConsistencyScore™: Consistency cannot yet be determined from the available evidence.

Ranked evidence signals

1
HbA1c
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study

Why this answer: This answer is based on a single supporting study.

Limitations

Only one supporting study is available.
Consistency cannot yet be determined.
Population details are unavailable.

View Full Evidence

Does Omnipod DASH Insulin Management System improve type 1 diabetes knowledge score?

Emerging Evidence

Omnipod DASH Insulin Management System appears to improve Type 1 diabetes knowledge score.

ConsistencyScore™: Consistency cannot yet be determined from the available evidence.

Ranked evidence signals

1
Type 1 diabetes knowledge score
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study

Why this answer: This answer is based on a single supporting study.

Limitations

Only one supporting study is available.
Consistency cannot yet be determined.
Population details are unavailable.

View Full Evidence

Does Insulin therapy improve type 1 diabetes knowledge score?

Emerging Evidence

Current evidence does not show a clear benefit of Insulin therapy for Type 1 diabetes knowledge score.

ConsistencyScore™: Consistency cannot yet be determined from the available evidence.

Ranked evidence signals

1
Type 1 diabetes knowledge score
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study

Why this answer: This answer is based on a single supporting study.

Limitations

Only one supporting study is available.
Consistency cannot yet be determined.
Population details are unavailable.

View Full Evidence

Learn how Evidence Intelligence™ works

Next steps

Continue your research

Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.

Evidence topics

Follow the topics this study contributes to.

HbA1c Reduction Evidence Hub Glycemic Control Evidence Hub Insulin Therapies Evidence Hub

Explore in Evidence Explorer

Open broader Evidence Explorer views for this relationship.

All studies on Insulin therapy and Type 1 diabetes knowledge score All studies on Omnipod DASH Insulin Management System and Type 1 diabetes knowledge score All studies on Insulin therapy and HbA1c All studies on Omnipod DASH Insulin Management System and HbA1c

Related research

Read related research summaries.

Semaglutide with Insulin Improves Diabetes Control and Kidney Health Vildagliptin improves glycemic control in type 2 diabetes patients on insulin Hybrid Closed-Loop Insulin Improves Glycemic Control in Youth QCC Model Enhances Diabetes Management Artificial pancreas may improve glucose control in type 1 diabetes

No ads. No tracking.

Focused on evidence, not advertising.

Secure & private

Your data is always protected.

Always up to date

New studies added every day.